{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T23:51:07Z","timestamp":1771026667425,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>\n                                 <jats:sup>177<\/jats:sup> Lu-DOTA-TATE (LUTATHERA) is a crucial radiopharmaceutical in neuroendocrine tumor therapy, yet real-world long-term safety data across diverse populations remain limited. This study aims to comprehensively assess the postmarketing safety of LUTATHERA using a real-world pharmacovigilance database.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted an observational study using the US Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS) database from the first quarter of 2018 to the third quarter of 2024. Reports were filtered for LUTATHERA as the primary suspect. The characteristics and onset time of LUTATHERA-associated adverse events were analyzed. The disproportionality analysis via reporting odds ratio (ROR) and Bayesian confidence propagation neural network was employed to identify significant adverse event signals associated with LUTATHERA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 4058 reports identified with LUTATHERA as the primary suspected drug. LUTATHERA was linked to increased risks in in general disorders, gastrointestinal, hematological, metabolic, hepatobiliary, and endocrine systems. Common adverse events like nausea, thrombocytopenia, and anemia aligned with clinical trial data. Novel and serious signals such as intestinal obstruction [ROR = 5.62, information component (IC) = 2.49], gastrointestinal hemorrhage (ROR = 2.84, IC = 1.50), carcinoid heart disease (ROR = 571.03, IC = 8.93), and esophageal varices hemorrhage (ROR = 11.92, IC = 3.57) were also identified. LUTATHERA-associated adverse events typically occurred within 2 months, with a median onset of 54 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study enhances understanding of LUTATHERA\u2019s safety profile, offers clinicians valuable data, and advocates continuous pharmacovigilance. Continuous pharmacovigilance and potential label updates are recommended.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002015","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T05:00:14Z","timestamp":1751259614000},"page":"905-912","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Postmarketing safety surveillance of 177Lu-DOTA-TATE (LUTATHERA): an observational, pharmacovigilance study leveraging FAERS database"],"prefix":"10.1097","volume":"46","author":[{"given":"Xinhua","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Natural Medicinal Chemistry, School of Pharmacy, Xi\u2019an Jiaotong University, Xi\u2019an"},{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4260-1794","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Natural Medicinal Chemistry, School of Pharmacy, Xi\u2019an Jiaotong University, Xi\u2019an"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"R1-20250911","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1158\/1078-0432.CCR-20-3453","article-title":"177Lu-DOTA-EB-TATE, a radiolabeled analogue of somatostatin receptor type 2, for the imaging and treatment of thyroid cancer.","volume":"27","author":"Thakur","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R2-20250911","doi-asserted-by":"crossref","first-page":"724","DOI":"10.6004\/jnccn.2012.0075","article-title":"Neuroendocrine tumors.","volume":"10","author":"Kulke","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"R3-20250911","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.semradonc.2020.07.007","article-title":"Radiopharmaceuticals for neuroendocrine tumors.","volume":"31","author":"Chin","year":"2021","journal-title":"Semin Radiat Oncol"},{"key":"R4-20250911","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/ph10010030","article-title":"Current status of radiopharmaceuticals for the theranostics of neuroendocrine neoplasms.","volume":"10","author":"Fani","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"key":"R5-20250911","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera\u00ae: the first FDA-and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy.","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"R6-20250911","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/14740338.2023.2278700","article-title":"Drug-induced hypoglycemia: a disproportionality analysis of the FAERS database.","volume":"23","author":"Li","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"R7-20250911","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","article-title":"A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.","volume":"19","author":"Peng","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"R8-20250911","doi-asserted-by":"crossref","first-page":"1283247","DOI":"10.3389\/fphar.2023.1283247","article-title":"Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"R9-20250911","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/14740338.2024.2371382","article-title":"Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database.","volume":"24","author":"Wan","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"R10-20250911","first-page":"1","article-title":"Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database.","volume":"1","author":"Wei","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"R11-20250911","doi-asserted-by":"crossref","first-page":"1368763","DOI":"10.3389\/fphar.2024.1368763","article-title":"Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharmacol"},{"key":"R12-20250911","doi-asserted-by":"crossref","first-page":"1389814","DOI":"10.3389\/fphar.2024.1389814","article-title":"Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) database.","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"R13-20250911","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The reporting of a disproportionality analysis for drug Safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration.","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"R14-20250911","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12859-019-2628-5","article-title":"Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.","volume":"20","author":"Wu","year":"2019","journal-title":"BMC Bioinf"},{"key":"R15-20250911","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio.","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R16-20250911","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","article-title":"Data mining spontaneous adverse drug event reports for safety signals in Singapore\u2013a comparison of three different disproportionality measures.","volume":"15","author":"Ang","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"R17-20250911","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00006982-200410000-00002","article-title":"Risks of intravitreous injection: a comprehensive review.","volume":"24","author":"Jager","year":"2004","journal-title":"Retina"},{"key":"R18-20250911","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3390\/pharmaceutics15041240","article-title":"Safety and therapeutic optimization of lutetium-177 based radiopharmaceuticals.","volume":"15","author":"Ladri\u00e8re","year":"2023","journal-title":"Pharmaceutics"},{"key":"R20-20250911","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s12020-024-03915-z","article-title":"Hematological toxicities with Lutathera\u00ae for neuroendocrine neoplasms: post-marketing surveillance data from the US-FDA.","volume":"86","author":"Grewal","year":"2024","journal-title":"Endocrine"},{"key":"R21-20250911","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3390\/cancers17091423","article-title":"Comparison of the hematotoxicity of PRRT with Lutathera\u00ae and locally manufactured 177Lu-HA-DOTATATE in patients with neuroendocrine tumors and the impact of different application intervals.","volume":"17","author":"Hofmann","year":"2025","journal-title":"Cancers"},{"key":"R22-20250911","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1186\/s12885-022-10443-4","article-title":"Aprospective, randomized, phase II study to assess the schemas of retreatment with Lutathera\u00ae in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH).","volume":"22","author":"Deshayes","year":"2022","journal-title":"BMC Cancer"},{"key":"R23-20250911","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1210\/endrev\/bnz004","article-title":"Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms.","volume":"41","author":"Hofland","year":"2020","journal-title":"Endocr Rev"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:00:37Z","timestamp":1757617237000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000002015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002015","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}